World Courier Authorized by UK Wholesale Distribution
Designed to ensure patients and patients in clinical trials safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive.
World Courier, a global provider in specialty logistics and an AmerisourceBergen company, has been granted Wholesale Distribution Authorization (WDA) by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). The WDA is a benchmark certifying the company’s quality systems and processes for storing and distributing pharmaceuticals.
Designed to ensure patients and patients in clinical trials safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive. MHRA regulations require WDA for companies that store shipments of pharmaceutical products for longer than 36 hours or have a refrigerated storage facility for pharmaceuticals. The company also met requirements to demonstrate compliance with the European Union’s Good Distribution Practice (GDP), guidelines that regulate the storage and transportation of medicinal products intended for human consumption.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL
July 29th 2025The application is backed by Phase III AMPLIFY trial results showing the oral combination significantly improved progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
J&J Submits sBLA to FDA for Tremfya Label Expansion Based on PsA Joint Damage Inhibition Data
July 29th 2025The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.
